Caladrius Biosciences (NASDAQ:CLBS) Share Price Crosses Above 200 Day Moving Average of $2.58

Shares of Caladrius Biosciences Inc (NASDAQ:CLBS) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.58 and traded as high as $2.67. Caladrius Biosciences shares last traded at $2.67, with a volume of 20,251 shares trading hands.

Separately, Zacks Investment Research cut Caladrius Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 14th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $8.63.

The company has a market capitalization of $27.46 million, a P/E ratio of -1.53 and a beta of 1.63. The business has a 50 day simple moving average of $2.42 and a 200-day simple moving average of $2.58.

Caladrius Biosciences (NASDAQ:CLBS) last posted its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). As a group, research analysts forecast that Caladrius Biosciences Inc will post -1.58 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Caladrius Biosciences stock. Vanguard Group Inc. raised its stake in Caladrius Biosciences Inc (NASDAQ:CLBS) by 7.6% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 207,973 shares of the biotechnology company’s stock after buying an additional 14,740 shares during the quarter. Vanguard Group Inc. owned approximately 2.00% of Caladrius Biosciences worth $474,000 as of its most recent SEC filing. 8.09% of the stock is owned by institutional investors.

Caladrius Biosciences Company Profile (NASDAQ:CLBS)

Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Featured Story: What is a bull market?

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.